Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacubitril + valsartan (Dr. Reddy's Laboratories)
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sacubitril + valsartan (Dr. Reddy's Laboratories) is a generic fixed-dose combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). This combination belongs to the class of angiotensin receptor-neprilysin inhibitors (ARNI). Sacubitril works by inhibiting neprilysin, an enzyme that degrades natriuretic peptides, thereby increasing their levels and promoting vasodilation and natriuresis. Valsartan blocks the AT1 receptor, counteracting the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This dual mechanism is primarily used for the treatment of chronic heart failure to reduce the risk of cardiovascular death and hospitalization. Dr. Reddy's Laboratories (Thailand) Limited has conducted bioequivalence studies to compare this formulation with the reference drug, Entresto.
- Other names
- Sacubitril and Valsartan Sodium TabletsSacubitril/Valsartan Dr. Reddy's
02
Targets
NEP (Neutral Endopeptidase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on sacubitril + valsartan (Dr. Reddy's Laboratories).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacubitril + valsartan (Dr. Reddy's Laboratories).